NFKB1 and cancer: They examined the effect of cisplatin, a standard chemotherapeutic agent, on a colon-26 (C26) murine cancer cachexia model and reported that although cisplatin is able to strongly reduce tumour burden, it can also promote muscle atrophy through the activation of the neuclear factor κ B (NF-κB) pathway.